Related Experiment Video
Updated: Aug 14, 2026
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
DNA-PK inhibition by M3814 enhances chemosensitivity in non-small cell lung cancer
Manni Wang1, Siyuan Chen1, Yuquan Wei1
1Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu 610000, China.
Abstract:
A significant proportion of non-small cell lung cancer (NSCLC) patients experience accumulating chemotherapy-related adverse events, motivating the design of chemosensitizating strategies. The main cytotoxic damage induced by chemotherapeutic agents is DNA double-strand breaks (DSB). It is thus conceivable that DNA-dependent protein kinase (DNA-PK) inhibitors which attenuate DNA repair would enhance the anti-tumor effect of chemotherapy. The present study aims to systematically evaluate the efficacy and safety of a novel DNA-PK inhibitor M3814 in synergy with chemotherapies on NSCLC. We identified increased expression of DNA-PK in human NSCLC tissues which was associated with poor prognosis. M3814 potentiated the anti-tumor effect of paclitaxel and etoposide in A549, H460 and H1703 NSCLC cell lines. In the four combinations based on two NSCLC xenograft models and two chemotherapy, we also observed tumor regression at tolerated doses in vivo. Moreover, we identified a P53-dependent accelerated senescence response by M3814 following treatment with paclitaxel/etoposide. The present study provides a theoretical basis for the use of M3814 in combination with paclitaxel and etoposide in clinical practice, with hope to aid the optimization of NSCLC treatment.
Insights
A novel DNA-PK inhibitor, M3814, enhances chemotherapy effectiveness in non-small cell lung cancer (NSCLC) by inhibiting DNA repair. This combination therapy shows promise for improved NSCLC treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Chemotherapy for non-small cell lung cancer (NSCLC) often leads to cumulative adverse events.
- DNA double-strand breaks (DSB) are a primary mechanism of chemotherapy-induced cytotoxicity.
- DNA-dependent protein kinase (DNA-PK) plays a crucial role in DNA repair, making it a potential target for chemosensitization.
Purpose of the Study:
- To evaluate the efficacy and safety of the novel DNA-PK inhibitor M3814 in combination with chemotherapy for NSCLC.
- To investigate the synergistic anti-tumor effects of M3814 with paclitaxel and etoposide.
Main Methods:
- Assessed DNA-PK expression in human NSCLC tissues and correlated it with prognosis.
- Evaluated M3814's potentiation of paclitaxel and etoposide in NSCLC cell lines (A549, H460, H1703).
- Tested the combination therapy in NSCLC xenograft models in vivo.
Main Results:
- Increased DNA-PK expression in NSCLC tissues was linked to poor prognosis.
- M3814 significantly enhanced the anti-tumor effects of paclitaxel and etoposide in vitro.
- Tumor regression was observed in vivo with M3814 combined with chemotherapy at tolerated doses.
- A P53-dependent accelerated senescence response was identified with M3814 and chemotherapy.
Conclusions:
- M3814 demonstrates synergistic anti-tumor activity with paclitaxel and etoposide in NSCLC.
- The combination therapy induces tumor regression and a P53-dependent senescence response.
- This study provides a rationale for using M3814 with paclitaxel and etoposide to optimize NSCLC treatment.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
